News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

Opinion|Videos|May 6, 2024

Importance of Early Diagnosis of Alzheimer’s Disease

Author(s)Richard Isaacson, MD, Sharon Cohen, MD, FRCPC, Marwan Sabbagh, MD

Key opinion leaders emphasize the significance of early diagnosis in Alzheimer's disease, as it allows patients to make autonomous decisions and access early treatment options, including potential participation in clinical trials.

Episodes in this series

EP. 1 Apolipoprotein E4 in Alzheimer’s Disease

EP. 1 Apolipoprotein E4 in Alzheimer’s Disease

EP. 2 Importance of Early Diagnosis of Alzheimer’s Disease

EP. 2 Importance of Early Diagnosis of Alzheimer’s Disease

Video 3 - "Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease"

EP. 3 Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease

video 4 - "Amyloid Cascade Hypothesis of Alzheimer’s Disease"

EP. 4 Amyloid Cascade Hypothesis of Alzheimer’s Disease

Video 5 - "Contribution of Multiple Pathways to the Development of Alzheimer’s Disease"

EP. 5 Contribution of Multiple Pathways to the Development of Alzheimer’s Disease

Video 6 - "Utilization of Neuroimaging in Alzheimer’s Disease"

EP. 6 Utilization of Neuroimaging in Alzheimer’s Disease

A panel of 3 experts on Alzheimer's disease

EP. 7 CSF Testing and Blood-based Biomarkers in Alzheimer’s Disease

A panel of 3 experts on Alzheimer's disease

EP. 8 Utilization of APOE4 Genotype in Management of Alzheimer’s Disease

A panel of 3 experts on Alzheimer's disease

EP. 9 Alzheimer’s Disease Pipeline

A panel of 3 experts on Alzheimer's disease

EP. 10 The Future Outlook for Alzheimer’s Disease

Video content above is prompted by the following question(s):

Discuss the importance of early diagnosis and treatment of Alzheimer’s disease.

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Content

Douglas Sproule, MD, MSc (Credit: BridgeBio)

BridgeBio Pursues FDA Submission for BBP-418 in LGMD2i/R9 After Positive Topline Phase 3 Results

ByIsabella Ciccone, MPH

November 13th 2025

Paul Melmeyer, MPP

Uniting Organizations to Collectively Advocate for Neuromuscular Diseases: Paul Melmeyer, MPP

ByPaul Melmeyer, MPP,Isabella Ciccone, MPH

November 13th 2025

Evolution of CIDP Clinical Trials and Patient Protection

ByAmit Sachdev, MD, MS

November 13th 2025

Therapeutic Potential and Early Promise Behind Stem Cell Therapy UX-DA001 in Parkinson Disease

November 13th 2025

Sara Pirzadeh-Miller, MS, CGC

How AI and Gene Therapy work in conjunction: Sara Pirzadeh-Miller, MS, CGC

BySara Pirzadeh-Miller, MS, CGC,Louie Pasculli

November 12th 2025

Latest CME

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

In-Person + Virtual Event

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

November 21, 2025

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

John F. Brandsema, MD; Abigail N. Schwaede, MD; Samuel J. Mackenzie, MD, PhD

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

James F. Howard Jr, MD

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Identifying and Treating CIDP in the Modern Era

Identifying and Treating CIDP in the Modern Era

Jeffrey A. Allen, MD; Karissa L. Gable, MD

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

John Brandsema, MD; Neelam Goyal, MD

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

John Brandsema, MD; Carla D. Zingariello, DO

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Abigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MD

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Gerald Bernard Appel, MD; Ellie Kelepouris, MD, FACP, FAHA

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

James F. Howard Jr, MD, FAAN

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Therapeutic Potential and Early Promise Behind Stem Cell Therapy UX-DA001 in Parkinson Disease

Fenebrutinib Hits Key Phase 3 Marks in Relapsing and Primary Progressive MS

FDA Clears Phase 2a Clinical Trial to Test JOTROL in Patients With Parkinson Disease

Overviewing Positive Early Data from ACHIEVE Trial of Zeleciment Basivarsen in DM1: Doug Kerr, MD, PhD

Evolution of CIDP Clinical Trials and Patient Protection

© 2025 MJH Life Sciences^®

All rights reserved.